What is HC Wainwright's Forecast for IPA FY2028 Earnings?

Key Points

• HC Wainwright has raised its FY2028 earnings per share (EPS) estimate for ImmunoPrecise Antibodies Ltd. to $0.11, up from $0.08, while maintaining a "Buy" rating and setting a price target of $5.00.
• The company's recent quarterly earnings showed a loss of ($0.04) EPS, missing estimates, with revenue at $5.06 million against expected $7.89 million.
• Institutional ownership of ImmunoPrecise Antibodies is currently at 6.70%, indicating some interest from hedge funds and institutional investors.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) - Investment analysts at HC Wainwright upped their FY2028 earnings per share (EPS) estimates for shares of ImmunoPrecise Antibodies in a report issued on Wednesday, July 30th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.11 per share for the year, up from their previous forecast of $0.08. HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies' current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies' FY2029 earnings at $0.19 EPS.

Separately, Wall Street Zen upgraded ImmunoPrecise Antibodies from a "sell" rating to a "hold" rating in a report on Saturday, August 2nd.

ImmunoPrecise Antibodies Price Performance

Shares of NASDAQ:IPA traded down $0.09 on Monday, reaching $1.80. The company's stock had a trading volume of 451,831 shares, compared to its average volume of 4,253,841. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.85 and a current ratio of 2.08. ImmunoPrecise Antibodies has a 52-week low of $0.27 and a 52-week high of $2.41. The company has a market cap of $83.26 million, a P/E ratio of -2.63 and a beta of 0.49. The company has a 50-day simple moving average of $1.30 and a 200 day simple moving average of $0.74.

ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). ImmunoPrecise Antibodies had a negative net margin of 122.10% and a negative return on equity of 40.62%. The firm had revenue of $5.06 million for the quarter, compared to analysts' expectations of $7.89 million.

Institutional Trading of ImmunoPrecise Antibodies

A hedge fund recently bought a new position in ImmunoPrecise Antibodies stock. Baader Bank Aktiengesellschaft bought a new position in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 26,961 shares of the company's stock, valued at approximately $29,000. Baader Bank Aktiengesellschaft owned 0.06% of ImmunoPrecise Antibodies as of its most recent SEC filing. 6.70% of the stock is currently owned by institutional investors and hedge funds.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.